Fig. 2
From: Inflammatory signaling pathways play a role in SYK inhibitor resistant AML
(A) Immunoblot showing NR3C1 overexpression in MV4-11 resistant cells. Burkitt lymphoma cell line Ramos, was used as a positive control for NR3C1 expression. GAPDH was used as a loading control. Representative images of three independent replicates are shown. (B) Confirmation of NR3C1 mRNA fold-change upregulation in resistant versus naive MV4-11 cells by qpCR (***P ≤ 0.001, Mann-Whitney test). (C) Immunoblot showing upregulation of BIM in dexamethasone treated, entospletinib resistant MV4-11 cells. Vinculin was used as a loading control. Representative images of two independent replicates are shown. (D) Immunoblot showing NR3C1 expression in naive and venetoclax resistant MV4-11 cells in comparison to Ramos control cells. GAPDH was used as a loading control. Representative images of three independent replicates are shown. (E) Immunoblot confirming overexpression of NR3C1 ORF in MV4-11 cells, as well as SYK expression. Alpha tubulin was used as a loading control. Original Blots are presented in Supplementary Fig. 3. (F) Viability analysis using an ATP-based luminescent assay with increasing concentrations of dexamethasone in NR3C1 ORF expressing MV4-11 cells. (G) Long-term viability assay in MV4-11 cells overexpressing NR3C1 ORF and treated with vehicle or 3 µmol/L entospletinib (Ento).
